HBPCF (Helix BioPharma) Institutional Ownership : 0.00% (As of Mar. 03, 2025)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Helix BioPharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Helix BioPharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Helix BioPharma's Float Percentage Of Total Shares Outstanding is 93.46%.

Helix BioPharma Institutional Ownership Historical Data

The historical data trend for Helix BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Institutional Ownership Chart

Helix BioPharma Historical Data

The historical data trend for Helix BioPharma can be seen below:

	2012-12-31	2013-01-31	2013-02-28	2013-03-31	2013-04-30	2013-05-31	2013-06-30	2013-07-31	2013-08-31	2013-09-30
Institutional Ownership	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02

Helix BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.